Patents by Inventor C. Richard Lyttle
C. Richard Lyttle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9555014Abstract: This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.Type: GrantFiled: May 19, 2014Date of Patent: January 31, 2017Assignee: Radius Health, Inc.Inventors: Louis O'Dea, C. Richard Lyttle, Jonathan Guerriero
-
Publication number: 20160022608Abstract: This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.Type: ApplicationFiled: May 19, 2014Publication date: January 28, 2016Applicant: Radius Health, Inc.Inventors: Louis O'Dea, C. Richard Lyttle, Jonathan Guerriero
-
Patent number: 8933130Abstract: The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.Type: GrantFiled: June 22, 2007Date of Patent: January 13, 2015Assignee: Radius Health, Inc.Inventors: C. Richard Lyttle, Bart Henderson, Gary Hattersley
-
Patent number: 8748382Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: April 3, 2012Date of Patent: June 10, 2014Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20130157955Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: April 3, 2012Publication date: June 20, 2013Applicants: Ipsen Pharma S.A.S., Radius Health, Inc.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20130053448Abstract: This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.Type: ApplicationFiled: May 12, 2011Publication date: February 28, 2013Inventors: Louis O'Dea, C. Richard Lyttle, Jonathan Guerriero
-
Patent number: 8148333Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: October 3, 2007Date of Patent: April 3, 2012Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20110124617Abstract: This invention relates to combination therapies for the treatment of breast cancer comprising administering to a subject in need thereof a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist, or an estrogen receptor downregulator) and to compositions (e.g., pharmaceutical compositions) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent. This invention also relates to a method of treating the side effects (e.g., vasomotor disturbances, osteoporosis and musculoskeletal complaints) associated with anti-estrogen therapy in a subject treated with one or more anti-estrogenic agents (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist or an estrogen receptor downregulator).Type: ApplicationFiled: May 7, 2009Publication date: May 26, 2011Inventors: C. Richard Lyttle, Gary Hattersley, Louis O'Dea
-
Publication number: 20110092425Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: August 12, 2010Publication date: April 21, 2011Applicants: Radius Health, Inc., Ipsen Pharma S.A.SInventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Patent number: 7803770Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: May 9, 2008Date of Patent: September 28, 2010Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20100105733Abstract: The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.Type: ApplicationFiled: June 22, 2007Publication date: April 29, 2010Inventors: C. Richard Lyttle, Bart Henderson, Gary Hattersley
-
Publication number: 20100029556Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: October 3, 2007Publication date: February 4, 2010Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20090227498Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: May 9, 2008Publication date: September 10, 2009Applicant: Radius Health, Inc.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Patent number: 7531564Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 11, 2006Date of Patent: May 12, 2009Assignee: WyethInventors: Michael S. Malamas, Robert E. McDevitt, Iwan Gunawan, Eric S. Manas, Michael D. Collini, Heather A. Harris, James C. Keith, Jr., Leo M. Albert, C. Richard Lyttle
-
Publication number: 20070167503Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 11, 2006Publication date: July 19, 2007Applicant: WyethInventors: Michael Malamas, Robert McDevitt, Iwan Gunawan, Eric Manas, Michael Collini, Heather Harris, James Keith, Leo Albert, C. Richard Lyttle
-
Publication number: 20030199562Abstract: This invention provides estrogen receptor modulators of formula I, having the structure 1Type: ApplicationFiled: December 4, 2002Publication date: October 23, 2003Applicant: WyethInventors: Michael S. Malamas, Robert E. McDevitt, Iwan Gunawan, Eric S. Manas, Michael D. Collini, Heather A. Harris, James C. Keith, Leo M. Albert, C. Richard Lyttle
-
Patent number: 5891644Abstract: A composition comprising a soluble peptide of about 23 kD to about 29 kD, capable of causing neutrophil and macrophage chemotaxis, and which is substantially similar to chemotactic factor from peritoneal fluid of mammals with minimal or moderate endometriosis.Type: GrantFiled: May 5, 1998Date of Patent: April 6, 1999Assignee: The Trustees of the University of PennsylvaniaInventor: C. Richard Lyttle
-
Patent number: 5877284Abstract: A composition comprising a soluble peptide of about 23 kD to about 29 kD, capable of causing neutrophil and macrophage chemotaxis, and which is substantially similar to chemotactic factor from peritoneal fluid of mammals with minimal or moderate endometriosis.Type: GrantFiled: June 2, 1995Date of Patent: March 2, 1999Assignee: The Trustees of the University of PennsylvaniaInventor: C. Richard Lyttle
-
Patent number: RE49444Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: December 24, 2020Date of Patent: March 7, 2023Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle, Zhengxin Dong